🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PALMIRA: Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With HR+/HER 2– Advanced #BreastCancer ascopubs.org/doi/full/10.12… The PALMIRA Phase II trial investigated whether rechallenging with palbociclib combined with a different endocrine

Which option would you recommend to premenopausal Tanja with congenital long QT syndrome and metastatic HR+ HER2- #BreastCancer? Compare your choice with panel recommendations from 11 multidisciplinary experts and with answers from your peers: ppcp.mirrorsmed.org/en/single-case… This case

Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates ascopubs.org/doi/10.1200/OP… This review explores how next-generation ADCs, particularly trastuzumab deruxtecan (T-DXd), have expanded 🧬HER2-targeted therapy in

>90% of the patients with HR+ mBC are eligible for T-DXd, a life prolonging drug Many, however, are still not recognized as eligible due to issues with HER2 testing (no IHC performed, no dissection of ultralow/null) In our latest review, we dive deep into this important topic👇

CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors Study uncovers how loss of CHD1 in SPOP-mutated #ProstateCancer drives castration resistance by reprogramming cholesterol

💫Sub-analysis of #APHINITY shows overweight/obesity (BMI≥25) at diagnosis linked to worse iDFS (aHR 1.27), DRFI (1.32), OS (1.38), 🆚normal weight. Weight change at 2 yrs had no impact. 🔗sciencedirect.com/science/articl… OncoAlert Matteo Lambertini, MD PhD Elisa Agostinetto Evandro de Azambuja, MD, PhD

Zanidatamab + chemo in mBC presented by Erika Hamilton, MD mPFS in HER2+ 10.3 mo (ORR 43%) ESMO - Eur. Oncology #ESMOBreast25 OncoAlert

Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients link.springer.com/article/10.100… This study investigated whether genetic variations in enzymes involved in tamoxifen metabolism influence early discontinuation of

Registrations to RENALC-BLADDR-PROSCA are now open➡️gu-global-forum.org/registration-2… Check out Dr. Petros Grivas’s reasons to attend this interactive forum, covering the latest updates in clinical practice of #RenalCancer, #BladderCancer and #ProstateCancer. 📍Join us live in Lisbon, or

Proud to see the results of our meta-analysis on BMI and breast cancer risk included in the #ESMObreast25 highlights! OncoAlert Elisa Agostinetto Evandro de Azambuja, MD, PhD

Super excited for the keynote lecture at #ESMOBreastBCY by Ann Partridge MD, MPH from Dana-Farber !!!!! ESMO - Eur. Oncology OncoAlert Dana-Farber’s Breast Oncology Center #ESMOBreast25 #ESMOambassadors FabriceAndre Rebecca Dent

What a fantastic keynote lecture at #ESMOBreastBCY by Ann Partridge MD, MPH from Dana-Farber…a decade of #BCY…what we have done and where we are going!!! ESMO - Eur. Oncology OncoAlert Dana-Farber’s Breast Oncology Center #ESMOBreast25 #ESMOambassadors FabriceAndre Rebecca Dent

With #ASCO25 approaching, we already look forward to our next webinar➡️Join Dr. Alicia Morgans and Dr. Karim Fizazi in a discussion on the latest data on mHSPC and mCRPC management, including a clinical case discussion on PEACE-3. ❗️Registrations are open:

Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer link.springer.com/article/10.100… Retrospective study evaluated the impact of neoadjuvant endocrine therapy💊 (NET) duration on tumor response in 104 patients

Advancing breast cancer treatment in the era of molecular diagnostics (Review Article) thebreastonline.com/article/S0960-… Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment sciencedirect.com/science/articl… systematic review and

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer out on Lancet Oncology thelancet.com/journals/lanon… In this multicentre, phase 2a study, the combination of zanidatamab—a HER2🧬targeted

Let's kick off #RENALC25 with a first case challenge! Manuel has a small renal mass in his only functional kidney. What now? 👉 Check out the case, vote on your preferred treatment option: renalc.mirrorsmed.org/en/single-case… and see what Dr. Pignot Géraldine would do!📽️ Want to be part of more case

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines europeanurology.com/article/S0302-… The 2025 European Association of Urology (EAU) guidelines for muscle-invasive and metastatic #BladderCancer (MMIBC) provide